Temozolomide

{
  "id": "MLC-T-ONC-008584",
  "term": "Temozolomide",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used alone or with radiation therapy to treat adults with glioblastoma or anaplastic astrocytoma (types of brain tumors). It is used in patients whose cancer is newly diagnosed or did not get better with other treatment. It is also being studied in the treatment of other types of cancer. Temozolomide damages the cell’s DNA and may kill cancer cells. It is a type of alkylating agent. Also called Temodar.",
    "A triazene analog of dacarbazine with antineoplastic activity. As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of DNA replication. Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system."
  ],
  "abbreviation": "TMZ",
  "synonyms": [
    "Temodar"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/temozolomide/"
}